FDA Clears Path for Generic METHERGINE Injections Sans Safety Worries
Published Date: 3/18/2026
Notice
Summary
The FDA has decided that METHERGINE injection wasn’t taken off the market because of safety or effectiveness problems. This means generic drug makers can now apply to sell their own versions, as long as they meet all the rules. Patients and healthcare providers can expect more affordable options soon, with no delays caused by safety concerns.
Analyzed Economic Effects
3 provisions identified: 2 benefits, 1 costs, 0 mixed.
Generics Can Apply to Sell METHERGINE
The FDA determined on March 18, 2026 that METHERGINE (methylergonovine maleate) injection, 0.2 mg/mL, was not withdrawn for reasons of safety or effectiveness. This allows manufacturers to submit abbreviated new drug applications (ANDAs) that refer to this listed drug and may be approved if they meet all other legal and regulatory requirements.
Patients May See Lower-Cost Options Soon
Because the FDA found on March 18, 2026 that METHERGINE (methylergonovine maleate) injection, 0.2 mg/mL, was not withdrawn for safety or effectiveness, generic versions may be approved. Patients and health care providers who use this drug can expect more affordable generic options to become available if ANDA applicants meet approval requirements.
ANDA Applicants May Need Updated Labeling
The FDA said it will continue to list METHERGINE (methylergonovine maleate) injection, 0.2 mg/mL, in the Orange Book's Discontinued Drug Product List but noted that if the Agency determines the drug's labeling should be revised to meet current standards, it will advise ANDA applicants to submit updated labeling. ANDA applicants may therefore need to prepare revised labeling if requested by FDA.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-06478 — Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY
The FDA has officially set the review period for VYLOY, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind VYLOY, giving them a chance to extend their patent protection and potentially boost profits. If anyone thinks the dates are wrong or wants to challenge the company’s review speed, they must act by June 2 or September 30, 2026.
2026-06481 — Determination of Regulatory Review Period for Purposes of Patent Extension; HYMPAVZI
The FDA has set the official review period for HYMPAVZI, a new human biological product, so its patent holder can apply for extra patent time. This affects the company behind HYMPAVZI and anyone interested in patent extensions. If you think the dates are wrong or want to challenge the company’s diligence, you have until June 2 or September 30, 2026, to speak up—potentially impacting patent length and market exclusivity.
2026-06480 — Determination of Regulatory Review Period for Purposes of Patent Extension; EMRELIS
The FDA has officially set the review period for EMRELIS, a medicine patent, so the patent owner can apply for extra protection time. If anyone thinks the dates are wrong, they have until June 2, 2026, to speak up. Also, people can challenge whether the patent owner was diligent during the review by September 30, 2026. This affects patent holders and could impact how long they keep exclusive rights to their product.
2026-06479 — Determination of Regulatory Review Period for Purposes of Patent Extension; ENFLONSIA
The FDA has set the official review period for ENFLONSIA, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind ENFLONSIA and anyone interested in patent rules. If you think the dates are wrong or want to challenge the company’s review speed, you have until June 2 or September 30, 2026, to speak up—potentially impacting patent length and market exclusivity.
2026-06477 — Determination of Regulatory Review Period for Purposes of Patent Extension; ENCELTO
The FDA has officially set the review period for ENCELTO, a medicine patent, so the company can apply to extend its patent protection. This affects the drug maker by potentially giving them more time to exclusively sell ENCELTO, which can mean more money. If anyone thinks the dates are wrong or the company wasn’t diligent, they have until June 2 or September 30, 2026, to speak up.
2026-06483 — Determination of Regulatory Review Period for Purposes of Patent Extension; INJECTAFER
The FDA has officially set the review period for INJECTAFER, a drug patent up for extension. This means the company can apply to extend their patent protection, potentially keeping their exclusive rights longer and impacting competition and pricing. If anyone thinks the dates are wrong or the company wasn’t diligent, they can speak up by June 2 or September 30, 2026.
Previous / Next Documents
Previous: 2026-05308 — Request Notice: Use of Foreign-Built Small Passenger Vessel in United States Coastwise Trade, M/V BROADWAY GIRL
The government is asking for your thoughts on letting a foreign-built small passenger boat, the M/V BROADWAY GIRL, operate in U.S. coastal waters carrying up to 12 paying passengers. This decision could affect U.S. boat builders and businesses that use American-made vessels. If you want to share your opinion, make sure to comment by April 17, 2026!
Next: 2026-05310 — Certain Chocolate Milk Powder and Packaging Thereof; Issuance of Civil Penalties and Termination of Enforcement Proceeding
Four California companies got hit with big fines—totaling over $5 million—for breaking rules about certain chocolate milk powder and its packaging. These penalties cover violations lasting from 2 to 18 days, and the enforcement case is now officially closed. If you’re in the chocolate milk biz, this is a clear message: follow the rules or pay up!
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in